<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3022">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 14, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04807699</url>
  </required_header>
  <id_info>
    <org_study_id>32449420.4.1001.5262</org_study_id>
    <nct_id>NCT04807699</nct_id>
  </id_info>
  <brief_title>Collaborative Network for Generating Scientific Evidence in COVID-19 For the Unified Health System in Brazil - RECOVER SUS-BRASIL</brief_title>
  <acronym>Recoversus</acronym>
  <official_title>Rede Colaborativa Para Geração de Evidência Científica em COVID-19 Para o Sistema Único de Saúde no Brasil - RECOVER SUS-BRASIL</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Evandro Chagas National Institute of Infectious Disease</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospital Universitario Pedro Ernesto</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universidade Federal do Rio de Janeiro</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Couto Maia/SES/BA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital São José de Doenças Infecciosas - HSJ / Secretaria de Saúde Fortaleza</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Estadual Sumaré Dr. Leandro Francheschini</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universidade Federal de Santa Maria</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Regional de São José - Dr. Homero de Miranda Gomes</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital dos Servidores do Estado do Rio de Janeiro</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Federal University of Minas Gerais</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Universitário Gaffrée Guinle</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Nossa Senhora da Conceicao</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Instituto de Infectologia Emílio Ribas</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Evandro Chagas National Institute of Infectious Disease</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The RECOVER SUS-BRASIL network, made up of excellent academic and research institutions, was&#xD;
      formed in response to the emergence of unprecedented public health related to SARS-CoV-2. The&#xD;
      Network's objectives are the production of scientific knowledge, the technical and scientific&#xD;
      strengthening of participating centers, the sharing of information and experiences with other&#xD;
      assistance services and the generation of evidence for public health policies in Brazil. The&#xD;
      present proposal aims to increase the magnitude of the Network, proposing two studies to&#xD;
      assess the epidemic of COVID-19 in Brazil. The first study deals with the establishment of a&#xD;
      prospective cohort of patients hospitalized for COVID-19. Through using standardized data&#xD;
      collection procedures, biological samples and biomarkers, this study will be able to describe&#xD;
      clinical presentation, severity, risk factors for worsening of the disease. Multiple clinical&#xD;
      outcomes of severity of disease, organ dysfunction, hospital mortality, length of hospital&#xD;
      stay, hospital readmission and early post-discharge death. Will be biomarkers of&#xD;
      inflammation, cellular and humoral immunity were also evaluated to study their association&#xD;
      with clinical outcomes, variability of SARS-CoV-2 and the development of immunity in infected&#xD;
      individuals through the detection and titration of neutralizing antibodies anti-SARS-CoV-2.&#xD;
      The second study 2 will evaluate the COVID-19 epidemic in people living with HIV / AIDS,&#xD;
      using SUS databases, such as SIM, SICLOM and SISCEL. This study is particularly relevant&#xD;
      since on the one hand it includes a population potentially at greater risk of developing&#xD;
      severe forms of the disease, given their underlying condition, as, on the other hand, they&#xD;
      are exposed chronically to drugs that could potentially have an effect on SARS-CoV-2.&#xD;
      Finally, a major objective of RECOVER SUS-BRASIL is integrate technical and scientific&#xD;
      capacities generating scientific production of high relevance and impact and strengthening&#xD;
      health and science throughout the country.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study 1 procedures are clinical and sociodemographic data collected through interview at&#xD;
      admission and results of complementary exams performed during hospitalization. Data will be&#xD;
      collected during the participant's inclusion visit (Day 0,equivalent to the date of hospital&#xD;
      admission) and subsequently according to in-hospital visits untill discharge moment.&#xD;
&#xD;
      The team of researchers will have access to the electronic medical record or, as the case, to&#xD;
      the paper medical record for the collection of data and variables of the study interest, and&#xD;
      questionnaires with specific questions from participants or family members.&#xD;
&#xD;
      A visit in 31-60 days will be made, by telephone contact, for the application by a health&#xD;
      professional of a questionnaire on mental health and verification of the occurrence of death&#xD;
      or hospital readmission. The mental health questionnaire includes tracking disorders, such&#xD;
      as: depression, anxiety, post-traumatic stress disorder, suicidal ideation and insomnia&#xD;
      [questionnaires PHQ-9, GAD-7, Abbreviated PCL-C and Index Severity of Insomnia], in addition&#xD;
      to a questionnaire on social support [MSPSS]. Patients identified with health disorders over&#xD;
      the telephone will be referred to specialized care by a psychiatrist. Study 2 - Data from&#xD;
      information systems drug dispensation (SICLOM -&#xD;
      http://www.aids.gov.br/pt-br/gestores/sistemas-de-informacao/sistema-de-controle-logistico-de&#xD;
      medicamentos-siclom), laboratory tests (SISCEL - http :&#xD;
      //www.aids.gov.br/pt-br/sistema-de-informacao/sistema-de-controle-de-exameslaboratoriais-da-r&#xD;
      ede-nacional-de-contagem-de), information on mortality (SIM - http://sim.saude.gov.br/) and&#xD;
      COVID-19 case notification database will be released to the Ministry of Health, with data&#xD;
      identified with patient name, mother's name and date of birth to enable the linkage process.&#xD;
      This sensitive data is obtained through specific forms, which include confidentiality clauses&#xD;
      of the data. All transport and storage of this data, whether by digital physical means (for&#xD;
      example, CD) or via the web, will be done in encrypted form with a strong algorithm. The&#xD;
      final database will be de-identified to guarantee the confidentiality of the participants.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">July 25, 2020</start_date>
  <completion_date type="Anticipated">March 25, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 25, 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>2 Months</target_duration>
  <primary_outcome>
    <measure>The main outcome of the study is hospital mortality</measure>
    <time_frame>25/05/2021</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>25/05/2021</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">3500</enrollment>
  <condition>Covid19</condition>
  <condition>Hospitalization</condition>
  <arm_group>
    <arm_group_label>Total participants</arm_group_label>
    <description>3500 participants that will have their medical forms checked</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Data collection</intervention_name>
    <description>Clinical and sociodemographic data collected through interview at admission and results of complementary tests performed during hospitalization.</description>
    <arm_group_label>Total participants</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adults aged 18 years. Hospitalized for suspicious signs and symptoms of COVID-19 infection&#xD;
        by the medical care team or confirmed by laboratory tests such as RT-PCR or rapid tests.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:Adults aged 18 years. Hospitalized for suspicious signs and symptoms of&#xD;
        COVID-19 infection by the medical care team or confirmed by laboratory tests such as RT-PCR&#xD;
        or rapid tests.&#xD;
&#xD;
        Exclusion Criteria:Patient or family member refusal&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital Couto Maia/SES/BA</name>
      <address>
        <city>Salvador</city>
        <state>Bahia</state>
        <zip>41332-150</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital São José de Doenças Infecciosas - HSJ / Secretaria de Saúde Fortaleza</name>
      <address>
        <city>Fortaleza</city>
        <state>Ceará</state>
        <zip>60455-610</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universidade Federal de Minas Gerais</name>
      <address>
        <city>Belo Horizonte</city>
        <state>Minas Gerais</state>
        <zip>31270-901</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Nossa Senhora da Conceição</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universidade Federal de Santa Maria/ Pró-Reitoria de PósGraduação e Pesquisa</name>
      <address>
        <city>Santa Maria</city>
        <state>Rio Grande Do Sul</state>
        <zip>97105-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital dos Servidores do Estado/RJ</name>
      <address>
        <city>Rio de Janeiro</city>
        <state>RJ</state>
        <zip>20221-161</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitário Gaffree e Guinle/HUGG/UNIRIO</name>
      <address>
        <city>Rio de Janeiro</city>
        <state>RJ</state>
        <zip>20270-004</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitário Pedro Ernesto/UERJ</name>
      <address>
        <city>Rio de Janeiro</city>
        <state>RJ</state>
        <zip>20551-030</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Infectologia Evandro Chagas (Fiocruz)</name>
      <address>
        <city>Rio de Janeiro</city>
        <state>RJ</state>
        <zip>21040-360</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universidade Federal do Rio de Janeiro</name>
      <address>
        <city>Rio de Janeiro</city>
        <state>RJ</state>
        <zip>21941-617</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Regional de São José</name>
      <address>
        <city>São José</city>
        <state>Santa Catarina</state>
        <zip>88103-310</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Estadual Sumaré Dr. Leandro Francheschini</name>
      <address>
        <city>Sumaré</city>
        <state>São Paulo</state>
        <zip>13174-530</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto de Infectologia Emílio Ribas</name>
      <address>
        <city>São Paulo</city>
        <zip>01246-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 18, 2021</study_first_submitted>
  <study_first_submitted_qc>March 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 19, 2021</study_first_posted>
  <last_update_submitted>March 18, 2021</last_update_submitted>
  <last_update_submitted_qc>March 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Evandro Chagas National Institute of Infectious Disease</investigator_affiliation>
    <investigator_full_name>Raquel Malaguthi de Souza</investigator_full_name>
    <investigator_title>Beatriz Grinsztejn, MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Covid-19</keyword>
  <keyword>hospitalization</keyword>
  <keyword>biomarkers</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

